NCT05126927View on ClinicalTrials.gov

A PET Imaging Agent to Assess the Level of Tumor Tissue-infiltrating CD8 + T Cells in Patients With Solid Tumors

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

November 2, 2021

Primary Completion Date

January 19, 2022

Study Completion Date

August 1, 2022

Conditions
Solid Tumor
Interventions
BIOLOGICAL

68Ga-NODAGA-SNA006

A PET contrast agent to assess the level of tumor tissue-infiltrating CD8 + T cells in patients with solid tumors

Trial Locations (1)

Unknown

The First Affiliated Hospital of Soochow University, Suzhou

Sponsors
All Listed Sponsors
collaborator

The First Affiliated Hospital of Soochow University

OTHER

lead

SmartNuclide Biopharma

INDUSTRY

NCT05126927 - A PET Imaging Agent to Assess the Level of Tumor Tissue-infiltrating CD8 + T Cells in Patients With Solid Tumors | Biotech Hunter | Biotech Hunter